Quick Answer
Perspective Therapeutics, Inc. reported R&D Expense of $84.22 million for fiscal year 2025.
Perspective Therapeutics, Inc. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $84.22M | +102.3% |
| 2024 | $41.64M | +95.4% |
| 2023 | $21.31M | +2319.0% |
| 2022 | $881.0K | +3.6% |
| 2022 | $850.0K | -40.4% |
| 2021 | $1.43M | +26.7% |
| 2020 | $1.13M | -23.6% |
| 2019 | $1.47M | -15.6% |
| 2018 | $1.75M | +80.9% |
| 2017 | $965.0K | +82.8% |
| 2016 | $528.0K | -14.1% |
| 2015 | $615.0K | -8.0% |
| 2014 | $668.8K | +6.6% |
| 2013 | $627.1K | -19.7% |
| 2012 | $780.6K | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $20.34M | +69.1% | +22.4% |
| June 30, 2025 | $16.62M | +79.2% | +16.0% |
| March 31, 2025 | $14.33M | +92.3% | +19.2% |
| September 30, 2024 | $12.03M | +116.6% | +29.7% |
| June 30, 2024 | $9.28M | +72.7% | +24.5% |
| March 31, 2024 | $7.45M | +125.2% | +34.2% |
| September 30, 2023 | $5.55M | +684.2% | +3.4% |
| June 30, 2023 | $5.37M | +574.6% | +62.3% |
- Perspective Therapeutics, Inc. showed an increase of +102.3% in R&D Expense compared to the prior fiscal year.
- Over the 2012–2025 period, Perspective Therapeutics, Inc.’s r&d expense has grown by 10688.8% (from $780.6 thousand to $84.22 million).
- The most recent figure is from Perspective Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 16, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: